BioMarin posts first $1 billion quarter, sets VOXZOGO PDUFA date for hypochondroplasiaNov 2Quarterly updateBiomarin Pharmaceutical Incvosoritide
Rafael's Cyclo Therapeutics files NDA for remibetadex in Niemann-Pick Disease Type COct 29Regulatory decisionRafael Holdings, Inc.Updated
Rafael Holdings' Phase 3 NPC trial misses primary endpoint, subgroup hits significanceSep 30Clinical readoutRafael Holdings, Inc.
Amicus reports FY2025 results as BioMarin merger deal proceedsJul 13PeopleBiomarin Pharmaceutical Inc